Hemab
Prafull S. Gandhi, PhD, MS, serves as Scientific Director at Hemab. He has 10+ years of experience within pre-clinical innovation, research, and project management. He specializes in protein structure, function, and engineering for drug discovery. Most recently, he worked as a Principal Scientist at Novo Nordisk, where he managed pre-clinical projects, characterized protein-protein interactions, and gained insight into the field of bleeding disorders. He has authored more than 15 articles in scientific journals and is an inventor of several patents. He holds an MS in Chemical Engineering from Missouri University of Science and Technology, United States and a PhD in Biochemistry and Molecular Biophysics from Washington University School of Medicine in St. Louis, United States.
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.